The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib study of safety, tolerability, and efficacy of R1507 a monoclonal antibody to IGF-1R in combination with multiple standard chemotherapy regimens in patients with advanced solid malignancies.
Daruka Mahadevan
No relevant relationships to disclose
Gregory Ryan Sutton
No relevant relationships to disclose
Rafael Arteta-Bulos
No relevant relationships to disclose
Chris J. Bowden
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Paul J. E. Miller
No relevant relationships to disclose
Rachel Elizabeth Swart
Honoraria - Genentech/Roche
Research Funding - Genentech/Roche
Mark S. Walker
Consultant or Advisory Role - Genentech
Pamela N. Munster
Research Funding - Genentech/Roche
Elizabeth Claire Dees
Research Funding - Genentech/Roche
John Marshall
Consultant or Advisory Role - Genentech/Roche
Honoraria - Genentech/Roche
Research Funding - Genentech/Roche
Omid Hamid
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Razelle Kurzrock
Research Funding - Genentech/Roche